Prosperini, Luca http://orcid.org/0000-0003-3237-6267
Annovazzi, Pietro
Boffa, Laura
Buscarinu, Maria Chiara
Gallo, Antonio
Matta, Manuela
Moiola, Lucia
Musu, Luigina
Perini, Paola
Avolio, Carlo
Barcella, Valeria
Bianco, Assunta
Farina, Deborah
Ferraro, Elisabetta
Pontecorvo, Simona
Granella, Franco
Grimaldi, Luigi M. E.
Laroni, Alice
Lus, Giacomo
Patti, Francesco
Pucci, Eugenio
Pasca, Matteo
Sarchielli, Paola
Ghezzi, Angelo
Zaffaroni, Mauro
Baroncini, Damiano
Buttari, Fabio
Centonze, Diego
Fornasiero, Arianna
Salvetti, Marco
Docimo, Renato
Signoriello, Elisabetta
Tedeschi, Gioacchino
Bertolotto, Antonio
Capobianco, Marco
Comi, Giancarlo
Cocco, Eleonora
Gallo, Paolo
Puthenparampil, Marco
Grasso, Roberta
Di Francescantonio, Valeria
Rottoli, Maria Rosaria
Mirabella, Massimiliano
Lugaresi, Alessandra
De Luca, Giovanna
Di Ioia, Maria
Di Tommaso, Valeria
Mancinelli, Luca
Di Battista, Giancarlo
Francia, Ada
Ruggieri, Serena
Pozzilli, Carlo
Curti, Erica
Tsantes, Elena
Palmeri, Barbara
Lapicci, Caterina
Mancardi, Giovanni Luigi
Uccelli, Antonio
Chisari, Clara
D’Amico, Emanuele
Cartechini, Elisabetta
Repice, Anna Maria
Magnani, Eliana
Massaccesi, Luca
Calabresi, Paolo
Di Filippo, Massimiliano
Di Gregorio, Maria
,
Funding for this research was provided by:
Sanofi-Genzyme (Not Applicable)
Article History
Received: 30 August 2018
Revised: 17 September 2018
Accepted: 18 September 2018
First Online: 26 September 2018
Compliance with ethical standards
:
: On behalf of all authors, the corresponding author states that there is no conflict of interest. LP: speaker honoraria from Almirall, Biogen, Genzyme, Novartis, Roche and Teva; consulting fees from Biogen, Genzyme and Novartis; research grant from Genzyme and Italian MS Society. PA: consulting and/or lecture fees from Mylan, Roche, Almirall e Merck, Biogen, Genzyme, Novartis and Teva. LB: lecture fees from Merck Serono and Teva. MCB: Merck Serono, Teva, Genzyme, Novartis (scientific board); Biogen, Teva (speaker). AG: speaker and consulting fees from Biogen, Sanofi-Genzyme, Merck Seronoand Teva. MM: honoraria from: Biogen, Novartis, Almirall, Teva. LM: speaking honoraria and/or consultant fees from Biogen, Merck Serono, Sanofi-Aventis, Teva, Novartis. LM: speaking honoraria and/or consultant fees from Biogen, Genzyme and Teva. PP: speaking honoraria and/or consultant fees from Biogen, Merck serono, Teva, Novartis and Genzyme. CA: speaking honoraria and/or consultant fees from Merck Serono, Novartis, Genzyme. VB: speaking honoraria and/or consultant fees from Biogen Idec, Merck Serono, Bayer, Sanofi- Genzyme, Novartis. AB: nothing to disclose. DF: scientific advisory board and speaker honoraria from Merck Serono, Biogen, Sanofi-Genzyme, Bayer Shering and Novartis. EF: nothing to disclose. AF: research funding and lecture fees from Sanofi-Aventis, Biogen Idec, Merck Serono and Novartis. FG: research funding from Sanofi-Aventis and Biogen; advisory boards and speaking honoroaria from Biogen, Novartis, Sanofi Aventis, Merck Serono and Roche. LMEG: scientific advisory board for Merck Serono; funding for travel or speaker honoraria from Merck Serono, Biogen, Sanofi-Aventis, Bayer Schering and Solvay Pharmaceuticals, Inc.; institutional research support form Teva Pharmaceuticals Industries Ltd, Biogen, Genzyme Corporation, Sanofi-Aventis, Merck Serono, Novartis and Eisai Inc.; research support from Merck Serono, Biogen and Ministero della Salute of Italy. AL: lecturing honoraria from Biogen, Novartis and Teva; consulting fees from Sanofi-Genzyme, Biogen, Merck, Roche; funding for travel from Sanofi-Genzyme, Biogen, Merck Serono, and Teva. GL: scientific advisory boards for Almirall, Novartis, Biogen Idec, Sanofi-Aventis, Genzyme and Bayer Schering; funding for travel and speaker honoraria from Sanofi-Aventis, Biogen Idec, Bayer Schering, Teva Neurosciences, Almirall, Genzyme and Novartis; research support from Novartis, ‘Fondazione C. Serono’, Biogen Idec, Bayer Schering and Sanofi-Aventis. FP: scientific advisory board for Almirall, Bayer, Biogen, Merck, Novartis, Sanofi-Genzyme, Roche and TEVA; fees for speaking activities by Almirall, Bayer, Biogen, Merck, Novartis, Sanofi-Genzyme and TEVA. EP: personal fees and non-financial support from Biogen Idec, Merck Serono, Teva, Genzyme and Novartis; non-financial support from “Associazione Marchigiana Sclerosi Multipla e Altre Malattie Neurologiche”. MP: nothing to disclose. PS: nothing to disclose.
: The present study was conducted after approval of the Ethics Committee of Sapienza University (application no. 2923/15 - RIF.CE: 3947 of 17 December 2015). All data were gathered after informed consent was obtained from each participant, in accordance with specific national laws and the ethics standards laid down in the 1964 Declaration of Helsinki and its later amendments. In no way this study did interfere in the care received by patients. Anonymized data will be shared upon request by the Principal Investigator (LP).